QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Canopy Growth Corporation (CGC)

Healthcare

No action
Fundamental
2
Sentiment
2
Technical
1

Do Nothing: fundamentalScore 2 and qualitativeScore 2 both sit below the required floor of 3 (hard overrides) and average 20-day dollar volume ≈ $1.69M fails the $5M liquidity floor; the chart is additionally a broken downtrend (price below every average, ADX 46.7, no reversal signal), so no bullish entry qualifies.

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

Canopy Growth Corporation, headquartered in Smiths Falls, Canada, is engaged in the cultivation, marketing, and retail of cannabis and hemp-derived products for recreational and therapeutic uses. The company operates primarily in Canada, the United States, and Germany, offering products such as dried cannabis flower, extracts, infused beverages, and vape cartridges under brands like Tweed and Spectrum Therapeutics.

Fundamental

weak
Fundamental2
Speculative turnaround

Canopy Growth is in the early stages of a turnaround with improving revenue but unresolved structural risks and cash losses.

Speculative, still-cash-burning cannabis producer with a real operating turnaround underway but unresolved structural risk: revenue re-accelerated (+17% in the first half of FY2027) and Adjusted EBITDA is close to breakeven, yet GAAP losses persist, operating and free cash flow remain negative, dilution is heavy, and the March 2026 restatement, unremediated material weakness, ongoing SEC investigation and certified class action weigh on quality. A net-cash balance sheet and the absence of any going-concern warning keep this above the bottom of the scale, but the risk/reward is not yet investable.

Sentiment

weak
Sentiment2
Flat sentiment

Media sentiment is flat, with no significant retail or legal developments to drive a change in outlook.

The dominant in-window driver is the Q2 FY2027 earnings print (2026-11-06, announced) and its reception is bearish — revenue of CAD $81.4M came in below the CAD $82.1M consensus with a wider net loss and the shares fell, so the +22% net-revenue and +141% international-growth framing is not a rewarded bullish leg, and the only other live item is a board-held reverse-split authority (ongoing_process, announced) with no implementation date. The measured sentiment delta is determinate but essentially flat (baseline ≈ -0.02 → scoring ≈ -0.05), retail is indeterminate because Reddit access was blocked, and the Red-Flag Screen is clean with no severe or moderate flag fired, so no cap applies and the setup resolves as weak post-event digestion with no forward-dated driver.

Technical

very weak
Technical1
Downtrend persists

The stock is in a downtrend below all moving averages with no reversal signals, indicating continued weakness.

CGC is in an established downtrend: at $0.5612 it trades below every tracked average (SMA20 0.66, SMA50 0.80, SMA200 0.97, EMA9 0.62, EMA21 0.67, WMA9 0.61, WMA21 0.64, DEMA14 0.58, TEMA14 0.58) after a steady series of lower highs from ~$1.00 in late August to the 2026-11-13 low of 0.5432, essentially a fresh 52-week low (quoted yearLow 0.543). Momentum is weak rather than repairing: RSI14 28.37 and Williams %R -91.85 are deeply oversold but show no bullish divergence, MACD line -0.06 sits below its -0.05 signal with a flat 0.00 histogram, and ADX14 46.66 confirms a very strong (downward) trend rather than an exhausted one. ATR14 0.05 is 8.91% of price — very high volatility with no base forming. Score 1 of 5: broken structure, bounce-only interest at best. Independently, Step 00 hard blocks bar any bullish action — fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, and average 20-day dollar volume (~$1.69M) is below the $5M liquidity floor — so no trade plan was constructed.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.